Clinical Trial Update: Safety Study of Latanoprost Slow Release Insert [Phase 1]

View source ↗

Summary

Phase 1 safety study of the latanoprost slow-release insert was terminated in participants with primary open-angle glaucoma or ocular hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Latanoprost Slow Release Insert (latanoprost)

Snippet

Sponsor: Daniel Moore | Conditions: Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 1 | Status: TERMINATED